Acorda Therapeutics (ACOR) Misses Q3 EPS by 15c; Reiterates AMPYRA Net Sales Guidance
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
Financial Fact:
Provision for income taxes: -3.02M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Provision for income taxes: -3.02M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of ($0.04), $0.15 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $135.61 million versus the consensus estimate of $134.01 million.
The Company is reiterating 2016 AMPYRA net sales guidance of $475-$485 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- 374Water Inc (SCWO) Misses Q2 EPS by 15c
- uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
